Sharp Brains: Brain Fitness and Cognitive Health News

Neuroplasticity, Brain Fitness and Cognitive Health News

Icon

Cognitive training, diet, exercise, and vascular management seen to improve cognition even in people with genetic predisposition for dementia (APOE e4)

___

How do genet­ics impact ear­ly inter­ven­tion for demen­tia? (Med­ical News Bul­letin):

Car­dio­vas­cu­lar and neu­ro­log­i­cal dis­eases, such as demen­tia, have been linked to dys­func­tion of a vari­a­tion of the apolipopro­tein E, or APOE, gene, called the APOE e4 allele…The Finnish Geri­atric Inter­ven­tion Study to Pre­vent Cog­ni­tive Impair­ment and Dis­abil­i­ty (FINGER) eval­u­at­ed whether the effec­tive­ness of lifestyle mod­i­fi­ca­tions for those at risk of Alzheimer’s dis­ease would be dif­fer­ent for those with or with­out the APOE e4 gene. Read the rest of this entry »

Study: Harnessing a virtual reality brain training game to diagnose mild cognitive impairment (MCI)

virtual supermarket.

Vir­tu­al real­i­ty brain train­ing game can detect mild cog­ni­tive impair­ment, a con­di­tion that often pre­dates Alzheimer’s dis­ease (press release):

Geek researchers demon­strat­ed the poten­tial of a vir­tu­al super­mar­ket cog­ni­tive train­ing game as a screen­ing tool for patients with mild cog­ni­tive impair­ment (MCI) among a sam­ple of old­er adults…

In an arti­cle pub­lished in the Jour­nal of Alzheimer’s Dis­ease, the researchers Read the rest of this entry »

CEO of Cambridge Cognition to speak at 2013 SharpBrains Summit

ruth-keir

Ruth Frances Keir runs Cam­bridge Cog­ni­tion (AIM: COG), one of the 10 Com­pa­nies to Watch in 2013/ 2014 accord­ing to our lat­est mar­ket report, which devel­ops and com­mer­cial­izes com­put­erised neu­ropsy­cho­log­i­cal tests used in a vari­ety of health­care and research set­tings. She joined the Cam­bridge Cog­ni­tion board ini­tial­ly in 2010 as a non-exec­u­tive direc­tor, bring­ing to it more than 26 years’ expe­ri­ence in research and busi­ness devel­op­ment posi­tions in the phar­ma­ceu­ti­cal indus­try, as well as a peri­od as Direc­tor of her own con­sul­tan­cy busi­ness, Archea Ltd.

–> To Learn More and Reg­is­ter, click on 2013 Sharp­Brains Vir­tual Sum­mit: Sep­tem­ber 19–20th, 2013

Cambridge Cognition, developer of computerised neuropsychological tests, to go public in the UK

cantabmobileCam­bridge Cog­ni­tion, one of the 10 Com­pa­nies to Watch in 2013/ 2014 accord­ing to our lat­est mar­ket report, just announced its plans to go pub­lic in the UK’s AIM mar­ket.

Cam­bridge Cog­ni­tion in £15M AIM IPO (Busi­ness Week­ly): “… the move will Read the rest of this entry »

Measuring and treating Chemo Brain

Chemo Brain’ After Breast Can­cer Backed by Study (US News):

Breast can­cer patients treat­ed with chemother­a­py are at risk for mild men­tal deficits known col­lec­tive­ly as “chemo brain,” a new study finds. Researchers at the Mof­fitt Can­cer Cen­ter in Tam­pa, Fla., reviewed exist­ing research on brain func­tion (“cog­ni­tive” func­tion­ing) in Read the rest of this entry »

Watch All Recordings Now (40+ Speakers, 12+ Hours)

About SharpBrains

As seen in The New York Times, The Wall Street Journal, BBC News, CNN, Reuters and more, SharpBrains is an independent market research firm tracking health and performance applications of brain science.

Follow us and Engage via…

twitter_logo_header
RSS Feed

Search for anything brain-related in our article archives

Enter Your Email to receive Sharp­Brains free, monthly eNewslet­ter:

Join more than 50,000 Sub­scribers and stay informed and engaged.